{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:37:55Z","timestamp":1768923475687,"version":"3.49.0"},"reference-count":106,"publisher":"Elsevier","isbn-type":[{"value":"9780323988537","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acc.2022.06.003","type":"book-chapter","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T22:27:49Z","timestamp":1659047269000},"page":"73-116","source":"Crossref","is-referenced-by-count":1,"title":["Advances in clinical antibiotic testing"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2022.06.003_bb0010","author":"WHO"},{"key":"10.1016\/bs.acc.2022.06.003_bb0015","author":"WHO"},{"key":"10.1016\/bs.acc.2022.06.003_bb0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(22)00091-5","article-title":"Antimicrobial resistance: time to repurpose the global fund","volume":"399","author":"The","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2022.06.003_bb0025","author":"WHO"},{"key":"10.1016\/bs.acc.2022.06.003_bb0030","year":"2015","journal-title":"Global Actopn Plan on Antimicrobioal Resistance"},{"key":"10.1016\/bs.acc.2022.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0040","series-title":"Clinical Breakpoints and Dosing of Antibiotics","author":"EUCAST","year":"2022"},{"issue":"Pt. A","key":"10.1016\/bs.acc.2022.06.003_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clinms.2018.11.001","article-title":"The role of mass spectrometry in antibiotic stewardship","volume":"14","author":"Zander","year":"2019","journal-title":"Clin. Mass Spectrom."},{"key":"10.1016\/bs.acc.2022.06.003_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic drug monitoring of antibiotics: defining the therapeutic range","volume":"44","author":"Abdul-Aziz","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106062","article-title":"Personalised antimicrobial dosing: standing on the shoulders of giants","volume":"56","author":"Wallenburg","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/bs.acc.2022.06.003_bb0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cpt.2190","article-title":"Too much of a good thing: Defining antimicrobial therapeutic targets to minimize toxicity","volume":"109","author":"Downes","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2022.06.003_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0000000000000941","article-title":"Therapeutic drug monitoring of antibiotic drugs in patients receiving continuous renal replacement therapy or intermittent hemodialysis: a critical review","volume":"44","author":"Matusik","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","article-title":"Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives","volume":"134","author":"de Velde","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/bs.acc.2022.06.003_bb0075","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/bs.acc.2022.06.003_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/bs.acc.2022.06.003_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/FTD.0000000000000919","article-title":"Therapeutic Drug Monitoring of Antimicrobial Drugs in Neonates: An Opinion Article","volume":"44","author":"Touw","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/bs.acc.2022.06.003_bb0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jocn.2021.06.040","article-title":"Unmasking antibiotic-associated neurological disorders: the underminer in Intensive Care Unit","volume":"91","author":"Xiao","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/17512433.2020.1759413","article-title":"The management of anti-infective agents in intensive care units: the potential role of a 'fast' pharmacology","volume":"13","author":"Cattaneo","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FTD.0000000000000949","article-title":"Antibiotic stewardship and therapeutic drug monitoring of beta-lactam antibiotics: is there a link?An Opinion Paper","volume":"44","author":"Richter","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0120","article-title":"A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients","volume":"40","author":"Heffernan","year":"2021","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FTD.0000000000000942","article-title":"Therapeutic drug monitoring of antibiotics in critically Ill patients: current practice and future perspectives with a focus on clinical outcome","volume":"44","author":"Koch","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0135","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1007\/s00330-021-08042-1","article-title":"Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study","volume":"31","author":"Bitencourt","year":"2021","journal-title":"Eur. Radiol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jiac.2019.01.011","article-title":"Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients","volume":"25","author":"Urakami","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijantimicag.2018.09.015","article-title":"Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution","volume":"53","author":"Galar","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/bs.acc.2022.06.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123131","article-title":"Determination of polymyxin B in dried blood spots using LC-MS\/MS for therapeutic drug monitoring","volume":"1192","author":"Huang","year":"2022","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/FTD.0000000000000934","article-title":"Therapeutic drug monitoring of antibiotic drugs: The role of the clinical laboratory","volume":"44","author":"Shipkova","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0165","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/dta.2253","article-title":"UPLC-MS\/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units","volume":"10","author":"El-Najjar","year":"2018","journal-title":"Drug Test Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.talanta.2013.07.043","article-title":"Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry","volume":"116","author":"Tsai","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/bs.acc.2022.06.003_bb0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpba.2013.11.004","article-title":"Simultaneous analysis of antibiotics in biological samples by ultra high performance liquid chromatography-tandem mass spectrometry","volume":"89","author":"Cazorla-Reyes","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jchromb.2014.04.029","article-title":"Simultaneous determination of seven beta-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies","volume":"960","author":"Sime","year":"2014","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchromb.2014.01.035","article-title":"A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography\/tandem mass spectrometry and its applicability to a clinical study","volume":"951\u2013952","author":"Bijleveld","year":"2014","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jchromb.2014.11.034","article-title":"Ultrafast quantification of beta-lactam antibiotics in human plasma using UPLC-MS\/MS","volume":"978\u2013979","author":"Carlier","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1179\/1973947814Y.0000000209","article-title":"Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"27","author":"Barco","year":"2015","journal-title":"J. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0200","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1515\/cclm-2014-0746","article-title":"Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS\/MS method with semi-automated sample preparation","volume":"53","author":"Zander","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0205","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4155\/bio-2016-0157","article-title":"Simultaneous assay of multiple antibiotics in human plasma by LC-MS\/MS: importance of optimizing formic acid concentration","volume":"9","author":"Chen","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/bs.acc.2022.06.003_bb0210","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchromb.2017.09.014","article-title":"A simple ultra-high-performance liquid chromatography-high resolution mass spectrometry assay for the simultaneous quantification of 15 antibiotics in plasma","volume":"1065-1066","author":"Lefeuvre","year":"2017","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jchromb.2017.06.014","article-title":"Simultaneous determination of nine beta-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography-tandem mass spectrometry","volume":"1060","author":"Abdulla","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpba.2018.01.031","article-title":"Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS\/MS method","volume":"152","author":"Paal","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0225","article-title":"Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation","volume":"62","author":"D'Cunha","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2019.02.037","article-title":"LC-MS\/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples","volume":"169","author":"Ferrari","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0235","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpba.2019.03.004","article-title":"UPLC\/MS\/MS assay for the simultaneous determination of seven antibiotics in human serum-application to pediatric studies","volume":"174","author":"Magreault","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FTD.0000000000000570","article-title":"Simultaneous quantification of nine antimicrobials by LC-MS\/MS for therapeutic drug monitoring in critically Ill patients","volume":"41","author":"Neugebauer","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0245","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00216-019-02285-0","article-title":"A 2D HPLC-MS\/MS method for several antibiotics in blood plasma, plasma water, and diverse tissue samples","volume":"412","author":"Rehm","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.acc.2022.06.003_bb0250","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cca.2020.11.001","article-title":"LC-MS\/MS method for nine different antibiotics","volume":"511","author":"Rehm","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2022.06.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113289","article-title":"HILIC LC-MS\/MS method for the quantification of cefepime, imipenem and meropenem","volume":"186","author":"Rehm","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122160","article-title":"Validation and clinical application of a multiplex high performance liquid chromatography\u2014tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections","volume":"1157","author":"Decosterd","year":"2020","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.acc.2022.06.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113273","article-title":"A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients","volume":"186","author":"Barco","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.acc.2022.06.003_bb0270","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/jalm\/jfab036","article-title":"Stability and validation of a high-throughput LC-MS\/MS method for the quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in serum","volume":"6","author":"Bjergum","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121214","article-title":"Quantification of 15 antibiotics widely used in the critical care unit with a LC-MS\/MS system: an easy method to perform a daily therapeutic drug monitoring","volume":"14","author":"Feliu","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/bs.acc.2022.06.003_bb0280","article-title":"Quantification of fosfomycin in combination with nine antibiotics in human plasma and cation-adjusted Mueller-Hinton II broth via LCMS","volume":"11","author":"Goh","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/bs.acc.2022.06.003_bb0285","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/FTD.0000000000000911","article-title":"Simultaneous measurement of 11 antibiotics for use in the intensive care unit by ultra-high performance liquid chromatography-tandem mass spectrometry","volume":"44","author":"Woksepp","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0290","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00927-20","article-title":"Liquid chromatography mass spectrometry detection of antibiotic agents in sputum from persons with cystic fibrosis","volume":"65","author":"Gallagher","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0295","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/FTD.0000000000000736","article-title":"Determination of total and unbound meropenem, imipenem\/cilastatin, and cefoperazone\/sulbactam in human plasma: application for therapeutic drug monitoring in critically Ill patients","volume":"42","author":"Rao","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000975","article-title":"Pre-analytical stability of flucloxacillin, piperacillin, tazobactam, meropenem, cefalexin, cefazolin, and ceftazidime in therapeutic drug monitoring: a structured review","author":"Mortensen","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0305","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/FTD.0000000000000953","article-title":"Quantification of antibiotics in patient samples: state of the art in standardization and proficiency testing","volume":"44","author":"Schneider","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/FTD.0000000000000950","article-title":"Understanding the pharmacokinetics of antibiotics in pregnancy: is there a role for therapeutic drug monitoring?A narrative review","volume":"44","author":"Stojanova","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0315","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jiac.2018.10.001","article-title":"Relationship between amikacin blood concentration and ototoxicity in low birth weight infants","volume":"25","author":"Endo","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0320","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1509","article-title":"A retrospective review of the efficiency of first-dose therapeutic drug monitoring of gentamicin, amikacin, and vancomycin in the pediatric population","volume":"60","author":"Lim","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0325","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/INF.0000000000003058","article-title":"Pediatric antibiotic stewardship: optimization of vancomycin therapy based on individual pharmacokinetics","volume":"40","author":"Kreitmeyr","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/bs.acc.2022.06.003_bb0330","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/jpc.14683","article-title":"Vancomycin therapeutic drug monitoring in paediatrics","volume":"56","author":"Patel","year":"2020","journal-title":"J. Paediatr Child Health"},{"key":"10.1016\/bs.acc.2022.06.003_bb0335","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/bcp.14084","article-title":"Vancomycin is commonly under-dosed in critically ill children and neonates","volume":"85","author":"Sosnin","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0340","article-title":"Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: a prospective population pharmacokinetic and simulation study","author":"Samb","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071401","article-title":"Optimizing antimicrobial drug dosing in critically Ill patients","volume":"9","author":"Povoa","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/bs.acc.2022.06.003_bb0350","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01831-21","article-title":"Combination of pharmacokinetic and pathogen susceptibility information to optimize meropenem treatment of gram-negative infections in critically Ill patients","volume":"66","author":"Liebchen","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0355","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/cc13865","article-title":"Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review","volume":"18","author":"Shekar","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/bs.acc.2022.06.003_bb0360","first-page":"493","article-title":"Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on extracorporeal life support","volume":"38","author":"Bougle","year":"2019","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0365","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2014.11.005","article-title":"beta-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: a case-control study","volume":"45","author":"Donadello","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/bs.acc.2022.06.003_bb0370","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s13054-014-0565-2","article-title":"The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study","volume":"18","author":"Shekar","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/bs.acc.2022.06.003_bb0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/ACO.0000000000000810","article-title":"Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?","volume":"33","author":"Abdul-Aziz","year":"2020","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0380","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/bs.acc.2022.06.003_bb0385","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1055\/s-0039-1693498","article-title":"Pharmacokinetics\/pharmacodynamics of beta-lactams and therapeutic drug monitoring: from theory to practical issues in the intensive care unit","volume":"40","author":"Williams","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0390","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13613-021-00917-2","article-title":"Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: results from the international A\u2014TEAMICU survey","volume":"11","author":"Lanckohr","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/bs.acc.2022.06.003_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106180","article-title":"Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices","volume":"56","author":"Imani","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/bs.acc.2022.06.003_bb0400","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"international society of anti-infective pharmacology, from therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2022.06.003_bb0405","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0041-1740972","article-title":"Antibiotic optimization in the intensive care unit","volume":"43","author":"Lizza","year":"2022","journal-title":"Semin. Respir. Crit Care Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0410","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14787210.2020.1788387","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in the ICU","volume":"18","author":"Dhaese","year":"2020","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10.1016\/bs.acc.2022.06.003_bb0415","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/bs.acc.2022.06.003_bb0420","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","article-title":"Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial","volume":"44","author":"Al-Sulaiti","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/bs.acc.2022.06.003_bb0425","article-title":"Therapeutic drug monitoring of vancomycin in neurosurgery patients, from trough concentration to area under the curve: a retrospective single center cohort study in a tertiary hospital","volume":"50","author":"Chen","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/bs.acc.2022.06.003_bb0430","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/DDDT.S285488","article-title":"Individualized vancomycin dosing with therapeutic drug monitoring and pharmacokinetic consultation service: a large-scale retrospective observational study","volume":"15","author":"Kim","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/bs.acc.2022.06.003_bb0435","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jpids\/piaa057","volume":"9","author":"Rybak","year":"2020","journal-title":"J. Pediatric. Infect. Dis. Soc."},{"key":"10.1016\/bs.acc.2022.06.003_bb0440","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1111\/bcp.14834","article-title":"Are vancomycin dosing guidelines followed?A mixed methods study of vancomycin prescribing practices","volume":"87","author":"Carland","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2022.06.003_bb0445","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s11096-021-01266-7","article-title":"Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life","volume":"43","author":"Van Der Heggen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/bs.acc.2022.06.003_bb0450","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-021-01266-7","article-title":"De Cock, Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units","author":"van der Veen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/bs.acc.2022.06.003_bb0455","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of beta-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/bs.acc.2022.06.003_bb0460","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies?A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0465","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0470","article-title":"Therapeutic drug monitoring of meropenem and piperacillin in critical illness-experience and recommendations from one year in routine clinical practice","volume":"9","author":"Scharf","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/bs.acc.2022.06.003_bb0475","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dky314","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures","volume":"73","author":"Wong","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106472","article-title":"Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia","volume":"59","author":"Gijsen","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/bs.acc.2022.06.003_bb0485","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/bs.acc.2022.06.003_bb0490","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13063-019-3437-x","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin\/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial","volume":"20","author":"Hagel","year":"2019","journal-title":"Trials"},{"key":"10.1016\/bs.acc.2022.06.003_bb0495","article-title":"Personalized antibiotic therapy for the critically Ill: implementation strategies and effects on clinical outcome of piperacillin therapeutic drug monitoring-a descriptive retrospective analysis","volume":"10","author":"Schrader","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/bs.acc.2022.06.003_bb0500","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","article-title":"Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience","volume":"47","author":"Richter","year":"2019","journal-title":"Infection"},{"key":"10.1016\/bs.acc.2022.06.003_bb0505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcrc.2021.09.011","article-title":"Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: a prospective observational study","volume":"67","author":"Liebchen","year":"2022","journal-title":"J. Crit. Care"},{"key":"10.1016\/bs.acc.2022.06.003_bb0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med."},{"key":"10.1016\/bs.acc.2022.06.003_bb0515","article-title":"Impact on antibiotic resistance, therapeutic success, and control of side effects in therapeutic drug monitoring (TDM) of daptomycin: a scoping review","volume":"10","author":"Osorio","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/bs.acc.2022.06.003_bb0520","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0000000000000196","article-title":"Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis","volume":"37","author":"Reiber","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.acc.2022.06.003_bb0525","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jfma.2020.06.011","article-title":"Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions","volume":"120","author":"Cheng","year":"2021","journal-title":"J. Formos Med. Assoc."},{"key":"10.1016\/bs.acc.2022.06.003_bb0530","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/bs.acc.2022.06.003_bb0535","article-title":"An approach to measuring colistin plasma levels regarding the treatment of multidrug-resistant bacterial infection","volume":"8","author":"Pacheco","year":"2019","journal-title":"Antibiotics (Basel)"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:59:19Z","timestamp":1753430359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242322000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323988537"],"references-count":106,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2022.06.003","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}